Skip to content 
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts. more
| Time Frame | SPTX | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 1.37% | 4.34% | -1.12% |
| 1-Month Return | 16.96% | 10.32% | 3.62% |
| 3-Month Return | 52.31% | 19.4% | 3.72% |
| 6-Month Return | 240250% | 12.03% | 11.5% |
| Dec '24 | Dec '25 | |||||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Cost of Revenue | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Profit | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Margin | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Operating Expenses | 52.42M | 87.29M | [{"date":"2024-12-31","value":60.05,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Operating Income | (52.42M) | (87.29M) | [{"date":"2024-12-31","value":-5241600000,"profit":false},{"date":"2025-12-31","value":-8729400000,"profit":false}] | |||
| Total Non-Operating Income/Expense | - | 24.59M | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Pre-Tax Income | (46.88M) | (74.11M) | [{"date":"2024-12-31","value":-4687900000,"profit":false},{"date":"2025-12-31","value":-7410800000,"profit":false}] | |||
| Income Taxes | - | 773.00K | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Income After Taxes | - | (74.88M) | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":-7488100000,"profit":false}] | |||
| Income From Continuous Operations | (46.88M) | (74.88M) | [{"date":"2024-12-31","value":-4687900000,"profit":false},{"date":"2025-12-31","value":-7488100000,"profit":false}] | |||
| Income From Discontinued Operations | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Net Income | (46.88M) | (74.88M) | [{"date":"2024-12-31","value":-4687900000,"profit":false},{"date":"2025-12-31","value":-7488100000,"profit":false}] | |||
| EPS (Diluted) | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
These ratios help you determine the liquidity of the company. Higher is better.
| SPTX | |
|---|---|
| Cash Ratio | 17.44 |
| Current Ratio | 18.00 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| SPTX | |
|---|---|
| ROA (LTM) | -18.90% |
| ROE (LTM) | -28.08% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| SPTX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.04 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.96 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| SPTX | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 3.07 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Seaport Therapeutics, Inc. Common Stock (SPTX) share price today is $24.035
Yes, Indians can buy shares of Seaport Therapeutics, Inc. Common Stock (SPTX) on Vested. To buy
Yes, you can purchase fractional shares of Seaport Therapeutics, Inc. Common Stock (SPTX) via the Vested app. You can start investing in Seaport Therapeutics, Inc. Common Stock (SPTX) with a minimum investment of $1.
You can invest in shares of Seaport Therapeutics, Inc. Common Stock (SPTX) via Vested in three simple steps:
The 52-week high price of Seaport Therapeutics, Inc. Common Stock (SPTX) is $26.32. The 52-week low price of Seaport Therapeutics, Inc. Common Stock (SPTX) is $0.01.
The price-to-earnings (P/E) ratio of Seaport Therapeutics, Inc. Common Stock (SPTX) is
The price-to-book (P/B) ratio of Seaport Therapeutics, Inc. Common Stock (SPTX) is 3.07
The dividend yield of Seaport Therapeutics, Inc. Common Stock (SPTX) is 0.00%
The market capitalization of Seaport Therapeutics, Inc. Common Stock (SPTX) is $1.31B
The stock symbol (or ticker) of Seaport Therapeutics, Inc. Common Stock is SPTX
Consider the share price of Seaport Therapeutics, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Seaport Therapeutics, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Seaport Therapeutics, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Seaport Therapeutics, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Seaport Therapeutics, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Seaport Therapeutics, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
